Digoxin
Top View
- PRAC Recommendations on Signals Adopted at the PRAC Meeting of 7-10 September 2015
- Review of Existing Classification Efforts
- The Trouble with Well Intended Polypharmacy in the Elderly
- Get in Rhythm with the Safe and Effective Use of Antiarrythmic Drugs
- XENICAL - Orlistat Capsule Roche Pharmaceuticals ------XENICAL® (Orlistat) CAPSULES
- The Selection and Use of Essential Medicines
- Medication Overdoses in the Emergency Department: Oral Hypoglycemic Agents, Atypical Antipsychotic Agents, Beta- Blockers, Calcium Channel Blockers, and Digoxin
- Pharmacometric Approach to Define Narrow Therapeutic Index (NTI) Drugs & Evaluate Bioequivalence (BE) Criteria for NTI
- Management of Acute Atrial Fibrillation and Atrial Flutter In
- LANOXIN (Digoxin) Is One of the Cardiac (Or Digitalis) Glycosides, a Closely Related Group of 8 Drugs Having in Common Specific Effects on the Myocardium
- Orlistat for the Treatment of Type I Hyperlipoproteinemia
- HIGH RISK DRUGS to AVOID in PATIENTS AGES 65 and OLDER Quick Reference Guide
- LANOXIN (Digoxin) Tablets, for Oral Use the Overall Incidence of Adverse Reactions with Digoxin Has Been Reported As Initial U.S
- Summary of Product Characteristics
- Bupropion Audit Criteria and Guidelines
- Comparing Drug-Class Membership in ATC and NDF-RT Fleur Mougin Anita Burgun Olivier Bodenreider Univ
- New Zealand Data Sheet
- Medicines for Cardiovascular Disease; (5Dec2017edition)(AIHW)